Login to Your Account



Financings NEWS

HONG KONG – Standing out of a crowd of more than 200 next-generation sequencing product developers in China, a 20-month-old company raised ¥150 million (US$23 million) in a follow-up series A financing.

Merus BV claimed the first tranche of a €72.8 million (US$80.5 million) series financing led by Sofinnova Ventures and Novo A/S, with additional backing from RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management, an unnamed U.S. investor and earlier supporters.

Flugen Inc. completed a $12.6 million series A financing to advance its plans to file an FDA investigational new drug application in the first half of next year, followed by a phase Ia study to look at safety and immune response in healthy adults.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: